Extremely well received!!!!! The preliminary safety and efficacy data from the Phase 1 trial were extremely well received by the scientific community during ASCO, where visitors to our poster presentation expressed deep interest in our novel SORT1 receptor target. As a recap, key highlights from this study included preliminary signs of antitumor activity noted in 36% activity pre-treated patients with two partial responses and seven patients with prolonged stable disease.
The above is what Paul said during the last CC
Question for Paul
Is your comment based on facts?